Free Trial
NASDAQ:UPB

Upstream Bio (UPB) Stock Price, News & Analysis

Upstream Bio logo
$8.64 -0.14 (-1.59%)
Closing price 05/16/2025 04:00 PM Eastern
Extended Trading
$8.64 0.00 (0.00%)
As of 05/16/2025 06:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Upstream Bio Stock (NASDAQ:UPB)

Key Stats

Today's Range
$8.62
$9.38
50-Day Range
$6.07
$10.15
52-Week Range
$5.14
$29.46
Volume
318,862 shs
Average Volume
326,656 shs
Market Capitalization
$464.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$56.50
Consensus Rating
Buy

Company Overview

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Upstream Bio, Inc. was incorporated in 2021 and is based in Waltham, Massachusetts.

Receive UPB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Upstream Bio and its competitors with MarketBeat's FREE daily newsletter.

UPB Stock News Headlines

The Robotics Revolution has arrived … and one $7 stock could take off as a result.
Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Revolution we predicted has arrived." In fact, I believe these robots could impact 65 million Americans lives — by August of this year.
See More Headlines

UPB Stock Analysis - Frequently Asked Questions

Upstream Bio's stock was trading at $16.44 at the beginning of the year. Since then, UPB shares have decreased by 47.4% and is now trading at $8.64.
View the best growth stocks for 2025 here
.

Upstream Bio, Inc. (NASDAQ:UPB) announced its earnings results on Tuesday, May, 6th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02. The company had revenue of $0.57 million for the quarter, compared to analysts' expectations of $0.71 million.

Upstream Bio (UPB) raised $200 million in an IPO on Friday, October 11th 2024. The company issued 12,500,000 shares at a price of $15.00-$17.00 per share. JPMorgan, TD Cowen, Piper Sandler and William Blair acted as the underwriters for the IPO.

Upstream Bio's lock-up period expired on Wednesday, April 9th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th. The total size of the offering was $255,000,000 based on an initial share price of $17.00. Since the expiration of Upstream Bio's lock-up period, restrictions preventing company insiders and major shareholders from selling shares in the company have been lifted.

Top institutional shareholders of Upstream Bio include Wellington Management Group LLP (2.44%), Siren L.L.C. (1.47%), Nantahala Capital Management LLC (1.11%) and Woodline Partners LP (1.04%). Insiders that own company stock include Erez Chimovits and Ai Upstream Llc.
View institutional ownership trends
.

Shares of UPB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
5/06/2025
Today
5/16/2025
Next Earnings (Estimated)
6/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:UPB
Previous Symbol
NASDAQ:UPB
Fax
N/A
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.50
High Stock Price Target
$75.00
Low Stock Price Target
$38.00
Potential Upside/Downside
+553.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.30 million
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$464.78 million
Optionable
N/A
Beta
N/A
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:UPB) was last updated on 5/17/2025 by MarketBeat.com Staff
From Our Partners